Drug facts
BrandTradjenta (Linagliptin)
No generic linagliptin has an active Orange Book listing (a generic was first approved 08/31/2021); the latest Tradjenta patent or exclusivity in the Orange Book runs to 12/08/2037.
Tradjenta was first approved by the FDA on 05/02/2011 under NDA 201280; the application holder is Boehringer Ingelheim Pharmaceuticals Inc.
The latest NADAC for TRADJENTA 5 MG TABLET is $16.80 per unit (as of 10/28/2026).
01Patents and exclusivity
When competition can legally begin. A generic can launch once both exclusivity and the last listed patent expire, unless a court or settlement says otherwise.
4,056days until the latest patent expires
- Latest patent
- 12/08/2037Tradjenta Orange Book
- Exclusivity
- 12/20/2026Tradjenta Orange Book
02Competition
- Generics
- No active generic listing in the Orange Book Orange Book
- First generic approved
- 08/31/2021 Orange Book
03Supply and price
- FDA drug shortage
- ClearNot on the current shortage list FDA shortages
- NADAC
- $16.80 per unitTRADJENTA 5 MG TABLET, as of 10/28/2026 CMS NADAC
04Product
- Application holder
- Boehringer Ingelheim Pharmaceuticals Inc Orange Book
- Application
- NDA 201280 Orange Book
- First approved
- 05/02/2011 Orange Book
- Dosage forms
- tablet
- Routes
- oral
Sources: FDA Orange Book, FDA Purple Book, FDA drug shortages, FDA enforcement reports and CMS NADAC, read through QOPE. Not medical or legal advice.